Skip to main content
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. — Investor Relations & Filings

Ticker · BEAM ISIN · US07373V1052 US Manufacturing
Open in API
Filings indexed 457 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US BEAM

About Beam Therapeutics Inc.

https://beamtx.com/

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines using its proprietary base editing technology. This approach is designed to make precise, single-letter edits to the genome without causing double-stranded breaks in the DNA, aiming to overcome the limitations of traditional gene editing methods. The company's pipeline focuses on creating potential life-long cures for genetic disorders, including sickle cell disease, beta-thalassemia, and alpha-1 antitrypsin deficiency. Beam Therapeutics is also advancing a suite of delivery technologies, such as electroporation, nonviral, and viral modalities, to deliver its base editors to target cells.

Recent filings

Filing Released Lang Actions
10-Q - Beam Therapeutics Inc. (0001745999) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Beam Therapeutics Inc. (0001745999) (Filer)
Regulatory Filings
2026-05-07 English
4 - BEAM THERAPEUTICS INC. (0001745999) (Filer)
Director's Dealing
2026-02-26 English
10-K - BEAM THERAPEUTICS INC. (0001745999) (Filer)
Annual Report FY 2025
2026-02-24 English
8-K - BEAM THERAPEUTICS INC. (0001745999) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 24, 2026. It details the entry into a material definitive agreement for a senior secured term loan facility of up to $500 million, including terms, covenants, and conditions. It also references a press release announcing quarterly financial results for the quarter ended December 31, 2025, but the press release is furnished as an exhibit and not the main content. The document primarily provides an update on financing activities and creation of a direct financial obligation. It does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). The focus on financing agreement details and related obligations aligns with a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8447 characters) supports it being a substantive filing rather than a brief announcement or certification.
2026-02-24 English
8-K - BEAM THERAPEUTICS INC. (0001745999) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a standby license agreement) and includes references to exhibits. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing reporting a material contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is just over 5,000 characters, so it is not a brief announcement but a full filing of the event.
2026-02-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.